Pharmaceutical Pricing Policy Reforms - 31st July 2026 - Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals - Gazette Notification PDF

Executive Summary The Department of Pharmaceuticals notified amendments to the Drugs (Prices Control) Order, 2013, on June 30, 2026, to promote ease of doing business and incentivize innovation in the pharmaceutical sector. Key reforms include revised liability for overcharging, simplified price adoption for new drugs, and a defined seven-year limit for record maintenance. These changes aim to reduce compliance burdens and facilitate speedier market launches for effective medications to improve patient access.

Key Points / Main Content

Pricing and Approvals

• Retail Price Adoption: Once the National Pharmaceutical Pricing Authority (NPPA) fixes a retail price for a new drug for one manufacturer, other manufacturers of the same formulation may adopt that price (or a lower one) for the next 12 months without seeking prior approval.
• Prior Approval Exemption: The amendment eliminates the need for individual prior price approvals for subsequent applications of existing manufacturers launching formulations with changed strengths, dosages, or combinations, provided a price has already been set by the NPPA.
• Incentivizing Innovation: The government may now fix separate ceiling or retail prices for the same drug if a separate price is justified by a therapeutic rationale that improves health outcomes.

Liability and Record Keeping

• Overcharging Liability: A manufacturer’s liability in overcharging cases is now restricted to the actual quantity of stock overcharged by the distributor, retailer, or stockist, provided DPCO 2013 provisions are met.
• Maintenance of Records: Manufacturers are now required to maintain records of sales for active pharmaceutical ingredients (APIs), bulk drugs, and formulations for a specific period of seven financial years immediately preceding the current financial year.

Impact Analysis

Drug Manufacturers Impact Manufacturers benefit from a significantly reduced compliance burden and speedier drug launches. They also face limited liability regarding overcharging by third-party distributors and gain financial incentives for developing drugs with superior therapeutic rationales. Action Required Manufacturers must ensure sales records are maintained for the mandatory seven-year period and may now adopt NPPA-fixed prices for new drugs within the 12-month window without filing for prior approval.

Consumers and Patients Impact Patients gain faster access to more effective, efficacious, and convenient drug formulations due to the removal of regulatory delays in pricing approvals. Action Required No specific action is required from this group.

Distributors, Retailers, and Stockists Impact The document clarifies that the manufacturer's liability is tied specifically to the quantity overcharged by these entities, emphasizing the need for compliance at the distribution level. Action Required These stakeholders must ensure compliance with DPCO 2013 provisions to avoid overcharging and ensure price transparency.

National Pharmaceutical Pricing Authority (NPPA) Impact The NPPA’s role is streamlined as it sets the initial benchmark price for new drugs, which subsequent manufacturers can then adopt, reducing the volume of individual prior-approval applications. Action Required The authority must continue to fix retail prices for new drugs and evaluate therapeutic rationales for requests regarding separate ceiling or retail prices.